A network for collaborative cancer research in Ontario

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The Marathon of Hope Cancer Centres Network (MOHCCN) aims to enhance cancer treatment through precision medicine by leveraging genomics and artificial intelligence. This observational study will enroll approximately 15,000 participants in its initial phase, with a long-term goal of reaching 100,000 participants over ten years. By analyzing individual variability in DNA, environment, and lifestyle, the study seeks to ensure that patients receive the most effective treatments tailored to their specific cancer types. The research will focus on various cancers, including breast, colorectal, pancreas, kidney, and prostate cancers.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients with histological and/or cytological confirmation of blood or solid tumor malignancies. For tumour types where pre-surgical biopsy is not routinely performed to confirm a pathologic diagnosis of cancer, patients may consent to this protocol, but eligibility must be confirmed after pathology is finalized demonstrating presence of malignancy
2. All patients must be able to satisfy the required minimum data elements for the 15k gold standard cohort through:

   1. Already existing data that satisfies the minimal requirements of a gold standard case (refer to Table 1)
   2. Have sufficient biospecimens (tumor and/or blood samples) available for more comprehensive molecular and immunophenotypic characterization
3. Patients who do not satisfy the required minimum data elements but would like to participate, maybe requested to donate blood and undergo a fresh biopsy if the archived Formalin-fixed paraffin-embedded (FFPE) samples are not available, or in cases where a fresh tumor biopsy is deemed necessary for molecular profiling.
4. Participating patients must agree to share their anonymized clinical and genomic data

Exclusion Criteria:

None.

Where it's running

• Kingston Health Sciences Centre
  Kingston, Ontario, Canada Recruiting
• Princess Margaret Cancer Centre
  Toronto, Ontario, Canada Recruiting
• Ottawa Health Research Institute
  Ottawa, Ontario, Canada Not yet recruiting

Study contacts

• Principal investigator: Lillian Siu, MD — University Health Network, Toronto
• Study coordinator: PM2C Central Office
• Email: MOHCCN@uhn.ca
• Phone: 416-946-4501

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using Riluzole to Help Breast Cancer Survivors with Cognitive Issues

  This study is testing if the medication riluzole can help breast cancer survivors who are having trouble with thinking and memory feel better.

  Recruiting Phase 2 University of California, Irvine · Orange, California · NCT06580002

• Validation of a blood test for early cancer detection and monitoring

  This study is testing a blood test to see if it can help find different types of cancer early and monitor patients after treatment.

  Recruiting at 3 sites Adela, Inc · Duarte, California and 16 other locations · NCT05366881

• Developing a liquid biopsy protocol for cancer research at Princess Margaret

  This study is trying to create a simple way to collect blood samples from cancer patients to see if analyzing certain molecules in their blood can help doctors understand their cancer better and track how it changes over time.

  Recruiting University Health Network, Toronto · Toronto, Ontario · NCT03702309

• Using brodalumab to treat immune-related side effects from cancer therapy

  This study is testing if brodalumab can help cancer patients who are having immune-related side effects from their immunotherapy treatment feel better.

  Recruiting Phase 1 Columbia University · New York, New York · NCT06673329

• Combination therapy using checkpoint inhibitors for advanced solid tumors

  This study is testing a new combination treatment using special antibodies for people with advanced solid tumors like lung and liver cancer to see if it can be safer and more effective than current options.

  Recruiting Phase 1/2 Second Affiliated Hospital of Guangzhou Medical University · Guangzhou, Guangdong · NCT05187338

• Evaluating progastrin levels in cancer patients

  This study is testing if measuring progastrin levels in the blood can help predict how cancer will progress and respond to treatment in patients with different types of cancer.

  Recruiting at 17 sites Hospices Civils de Lyon · Bron and 16 other locations · NCT03787056

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.